Pacific Biosciences of California, Inc.

As of June 30, 2026, Pacific Biosciences of California, Inc. carries a market capitalization of 8.63B, placing it among publicly traded companies globally. Its enterprise value stands at 16.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pacific Biosciences of California, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Pacific Biosciences of California, Inc. has 310.81M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.04, and the price-to-book ratio stands at -14.87.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 16.82B versus a market cap of 8.63B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pacific Biosciences of California, Inc. maintains a current ratio of 4.92, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2,126.06, indicating conservative leverage, while an interest coverage ratio of -15.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -16.66, reflecting losses generated across the asset base. The company generates approximately 5.48M in revenue per employee across its workforce of 507.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.76 indicates how many times Pacific Biosciences of California, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pacific Biosciences of California, Inc. recorded 14.45M in income tax expense. The company reported a pretax loss of -2.28B and -2.30B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 1, 2026, Pacific Biosciences of California, Inc.'s stock has gained approximately 89.02% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Pacific Biosciences of California, Inc. generated 2.78B in revenue and converted that into -2.30B in net income, yielding earnings per share of -7.53. EBITDA reached -2.02B, while operating income came in at -3.12B.

As of June 30, 2026, Pacific Biosciences of California, Inc. holds 4.14B in cash and equivalents against 12.34B in total debt, resulting in a net debt position of 10.19B. Total book value stands at -580.28M, with working capital of 4.71B providing operational flexibility.

Pacific Biosciences of California, Inc. produced -2.06B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -217.15M in capital expenditures, free cash flow totaled -2.28B - equivalent to -7.48 per share.

Over the twelve months ended June 30, 2026, Pacific Biosciences of California, Inc. posted a gross margin of 36.38, reflecting its pricing power and cost economics. The operating margin of -112.28 and net profit margin of -82.49 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -26.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.64, meaning Pacific Biosciences of California, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Pacific Biosciences of California, Inc. has an Altman Z-Score of -9.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.